EP
CRSP icon

Elkhorn Partners’s CRISPR Therapeutics CRSP Stock Holding History

Elkhorn Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
2,000
+100
+5% +$5.27K 0.09% 29
2026
Q1 		$90.4K Buy
1,900
+240
+14% +$12.7K 0.06% 30
2025
Q4 		$87K Sell
1,660
-540
-25% -$32.3K 0.06% 29
2025
Q3 		$143K Sell
2,200
-1,800
-45% -$103K 0.1% 21
2025
Q2 		$195K Sell
4,000
-200
-5% -$7.74K 0.14% 20
2025
Q1 		$143K Buy
4,200
+400
+11% +$17K 0.09% 21
2024
Q4 		$150K Buy
3,800
+700
+23% +$33.1K 0.1% 22
2024
Q3 		$146K Buy
3,100
+2,100
+210% +$107K 0.09% 23
2024
Q2 		$54K Buy
+1,000
New +$57.8K 0.04% 36
2023
Q4 		– Sell
-250
Closed -$11K – 50
2023
Q3 		$11K Buy
250
+220
+733% +$11.4K 0.01% 46
2023
Q2 		$2K Sell
30
-570
-95% -$32.3K ﹤0.01% 48
2023
Q1 		$27K Sell
600
-750
-56% -$36.4K 0.02% 41
2022
Q4 		$55K Buy
+1,350
New +$71.6K 0.04% 29
2022
Q2 		– Sell
-550
Closed -$35K – 49
2022
Q1 		$35K Buy
550
+200
+57% +$12.6K 0.02% 39
2021
Q4 		$27K Buy
350
+225
+180% +$19.7K 0.02% 36
2021
Q3 		$14K Hold
125
– – 0.01% 40
2021
Q2 		$20K Buy
+125
New +$15.2K 0.01% 37

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Elkhorn Partners's CRSP Position: Q2 2026 in Review

Elkhorn Partners increased its CRISPR Therapeutics (CRSP) stake by 5.3% in Q2 2026, buying an estimated $5.27K and bringing the position to 2,000 shares worth $109K. The position accounts for 0.09% of the portfolio, ranked #29.

Elkhorn Partners first reported a position in CRSP in Q2 2021 and has held it in 17 quarters since. The position peaked at $195K in Q2 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Elkhorn Partners held 2,000 shares of CRISPR Therapeutics worth $109K as of Q2 2026.
  • Elkhorn Partners bought 100 CRISPR Therapeutics shares in Q2 2026, an estimated $5.27K.
  • CRISPR Therapeutics made up 0.09% of Elkhorn Partners's portfolio in Q2 2026, its #29 holding.
  • Elkhorn Partners first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Elkhorn Partners's CRISPR Therapeutics position peaked at $195K in Q2 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Elkhorn Partners's 13F filing for Q2 2026, filed 13 Aug 2026.